Scott Moomaw, serving as Chief Commercial Officer for Liquidia Corp (NASDAQ:LQDA), has executed a significant divestment of company equity, according to recent regulatory disclosures. A Form 4 filing submitted to the Securities and Exchange Commission details the sale of 9,539 shares of Liquidia common stock, resulting in proceeds of $682,141. The transaction was finalized on July 13, 2026, with execution prices varying between $71.39 and $71.52 per share. This sale activity occurs against a backdrop of substantial stock appreciation, as shares have since advanced to $76.47, marking a 427% return over the trailing twelve-month period.
The divestment was structured under a Rule 10b5-1 trading plan established by Moomaw on December 15, 2023. The primary objective of this sale was to generate liquidity for tax obligations associated with the settlement of previously awarded restricted stock units (RSUs) and performance stock units (PSUs). Prior to the execution of these sales, Moomaw had acquired 7,466 shares on July 10, 2026. These acquisitions resulted from the conversion of performance stock units, which translate into common stock on a one-for-one basis. Following the completion of these transactions, Moomaw’s direct ownership in Liquidia stands at 182,485 shares. This position encompasses various unvested restricted stock units as well as shares procured through the company’s Employee Stock Purchase Plan.
Market analysts are recalibrating their assessments of Liquidia following recent corporate developments. BofA Securities has downgraded its rating for the stock from Buy to Neutral, citing a more balanced risk-reward profile following a robust performance year-to-date. Despite the downgrade, the firm raised its price target to $79 from $64, indicating elevated expectations for peak sales of Yutrepia, now projected at $2.2 billion. Conversely, H.C. Wainwright has maintained a Buy rating while increasing its price target to $75. This adjustment follows favorable legal developments, specifically a Supreme Court ruling involving Hikma Pharmaceuticals and Amarin, which is viewed as advantageous to Liquidia’s ongoing litigation. Raymond James has also reiterated a Strong Buy rating with a $68 price target, emphasizing the positive implications of the same judicial decision.
Corporate structural changes are also underway for Liquidia. The company is scheduled to join the S&P SmallCap 600 Index, effective June 22. This inclusion marks a significant milestone for the firm, placing it within an index that tracks small-cap U.S. companies. According to InvestingPro analysis, the company remains undervalued at current levels, with data highlighting a 92% gross profit margin and 18 additional ProTips available to subscribers regarding profitability metrics.
Key Points
- Insider Activity: CCO Scott Moomaw sold $682,141 worth of stock under a pre-arranged plan to cover tax liabilities from RSU and PSU settlements, retaining a substantial direct holding of 182,485 shares.
- Analyst Revisions: Mixed analyst sentiment is evident, with BofA Securities downgrading to Neutral but raising its price target to $79, while H.C. Wainwright and Raymond James maintain Buy ratings citing legal wins and Yutrepia sales potential.
- Index Inclusion: Liquidia is set to join the S&P SmallCap 600 Index on June 22, enhancing its visibility within the small-cap sector and potentially altering institutional ownership dynamics.
Risks and Uncertainties
- Valuation and Execution: Despite high gross margins, BofA Securities notes a more balanced risk-reward profile, suggesting that the stock’s recent 427% return may have priced in much of the positive outlook, creating uncertainty around future upside relative to the $79 price target.
- Litigation Dependency: Analyst upgrades from H.C. Wainwright and Raymond James are explicitly tied to a Supreme Court ruling involving Hikma Pharmaceuticals and Amarin. This creates a dependency on external legal outcomes, introducing uncertainty regarding the duration and impact of these favorable legal developments on long-term valuation.
- Index Transition Dynamics: The transition into the S&P SmallCap 600 Index may introduce volatility as institutional rebalancing occurs. While this inclusion signals growth, the mechanics of index tracking can lead to short-term price fluctuations as funds adjust their holdings to match the new index composition.